Trial Profile
A Phase 1 Study of HSB-1216 in Adult Subjects with Relapsed Tumors, or Who have Metastatic Small Cell Lung Cancer (SCLC) with Progression on or After Platinum-Based Chemotherapy (relapsed SCLC).
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Salinomycin (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- 13 Apr 2023 According to Hillstream Biopharma media release, the company expect to initiate this study in the second half of 2023.
- 10 Apr 2023 According to Hillstream Biopharma media release, the company expect to submit IND in the second half of 2023 with HSB-1216.
- 17 Jan 2023 According to Hillstream Biopharma media release, the company intends to initate IND discussions with the FDA in first half of 2023.